Home Cart Sign in  
Chemical Structure| 1695533-89-1 Chemical Structure| 1695533-89-1

Structure of KO-947
CAS No.: 1695533-89-1

Chemical Structure| 1695533-89-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential clinical utility in MAPK pathway dysregulated tumors.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KO-947

CAS No. :1695533-89-1
Formula : C21H17N5O
M.W : 355.39
SMILES Code : O=C(NC1=C(C=C2C(NN=C2C3=CC=NC=C3)=C1)C4)N4CC5=CC=CC=C5
MDL No. :MFCD31657422
InChI Key :ODIUJYZERXVGEI-UHFFFAOYSA-N
Pubchem ID :136653617

Safety of KO-947

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of KO-947

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U118MG-R cells 10 μM Investigate the inhibitory effect of KO-947 on ERK phosphorylation PMC9627366
T98G-R cells 10 μM Investigate the inhibitory effect of KO-947 on ERK phosphorylation PMC9627366

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
J:NU mice Subcutaneous tumor model Intraperitoneal injection 50 mg/kg Single dose, imaging after 2 hours Evaluate the inhibitory effect of KO-947 on ERK in subcutaneous tumor model, results showed significant signal increase PMC10141594

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03051035 Advanced Malignant Neoplasm PHASE1 TERMINATED 2020-06-02 Mayo Clinic, Rochester, Minnes... More >>ota, 55902, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111-2497, United States|Vall D'Hebron Institute of Oncology, Barcelona, 08035, Spain|START Madrid-HM CIOCC, Madrid, 28050, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.07mL

2.81mL

1.41mL

28.14mL

5.63mL

2.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories